Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia

Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching

“…28 These new antifungal drugs have not yet been compared with CCAB, only with c-AmB. 1,11,12,29,30 Our results are in line with other studies investigating CCAB, which showed that renal dysfunction was mild and reversible. In these reports, several patient groups were studied, including ICU patients.…”

“…In addition, no studies demonstrate superior efficacy or mortality reduction of other antifungal treatments like the newer azoles or echinocandins over CCAB. 1,2,19,31,39 Based on our findings and the above-mentioned considerations, CCAB should be considered as a safe, first-line antifungal in critically ill patients with suspected or documented invasive candidiasis pending confirmation or exclusion of diagnosis and identification of the organism. 31 A strength of our findings is that all results support the same conclusion.…”

Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching

“…28 These new antifungal drugs have not yet been compared with CCAB, only with c-AmB. 1,11,12,29,30 Our results are in line with other studies investigating CCAB, which showed that renal dysfunction was mild and reversible. In these reports, several patient groups were studied, including ICU patients.…”

“…In addition, no studies demonstrate superior efficacy or mortality reduction of other antifungal treatments like the newer azoles or echinocandins over CCAB. 1,2,19,31,39 Based on our findings and the above-mentioned considerations, CCAB should be considered as a safe, first-line antifungal in critically ill patients with suspected or documented invasive candidiasis pending confirmation or exclusion of diagnosis and identification of the organism. 31 A strength of our findings is that all results support the same conclusion.…”

Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment

“…This marked reduction of nephrotoxicity observed in continuous infusion group is comparable with that observed in patients treated with liposomal amphotericin B. As no difference was observed in hypokalaemia, similarly to the studies with liposomal amphotericin B, the continuous infusion of amphotericin B deoxycholate appears to reduce mainly pretubular renal toxicity 1,22 …”

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia

“…Furthermore, it appeared that the trial authors did not use premedication for prevention of infusion related toxicity, or supplementation with fluid, potassium and magnesium for prevention of nephrotoxicity although these precautions were known to be highly e ective when the trial was planned. Such preventive measures have been reported in other trials we have reviewed (Johansen 2000).…”

Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching

“…28 These new antifungal drugs have not yet been compared with CCAB, only with c-AmB. 1,11,12,29,30 Our results are in line with other studies investigating CCAB, which showed that renal dysfunction was mild and reversible. In these reports, several patient groups were studied, including ICU patients.…”

“…In addition, no studies demonstrate superior efficacy or mortality reduction of other antifungal treatments like the newer azoles or echinocandins over CCAB. 1,2,19,31,39 Based on our findings and the above-mentioned considerations, CCAB should be considered as a safe, first-line antifungal in critically ill patients with suspected or documented invasive candidiasis pending confirmation or exclusion of diagnosis and identification of the organism. 31 A strength of our findings is that all results support the same conclusion.…”

Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment

“…This marked reduction of nephrotoxicity observed in continuous infusion group is comparable with that observed in patients treated with liposomal amphotericin B. As no difference was observed in hypokalaemia, similarly to the studies with liposomal amphotericin B, the continuous infusion of amphotericin B deoxycholate appears to reduce mainly pretubular renal toxicity 1,22 …”

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia

“…Furthermore, it appeared that the trial authors did not use premedication for prevention of infusion related toxicity, or supplementation with fluid, potassium and magnesium for prevention of nephrotoxicity although these precautions were known to be highly e ective when the trial was planned. Such preventive measures have been reported in other trials we have reviewed (Johansen 2000).…”

Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching

“…28 These new antifungal drugs have not yet been compared with CCAB, only with c-AmB. 1,11,12,29,30 Our results are in line with other studies investigating CCAB, which showed that renal dysfunction was mild and reversible. In these reports, several patient groups were studied, including ICU patients.…”

“…In addition, no studies demonstrate superior efficacy or mortality reduction of other antifungal treatments like the newer azoles or echinocandins over CCAB. 1,2,19,31,39 Based on our findings and the above-mentioned considerations, CCAB should be considered as a safe, first-line antifungal in critically ill patients with suspected or documented invasive candidiasis pending confirmation or exclusion of diagnosis and identification of the organism. 31 A strength of our findings is that all results support the same conclusion.…”

Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment

“…This marked reduction of nephrotoxicity observed in continuous infusion group is comparable with that observed in patients treated with liposomal amphotericin B. As no difference was observed in hypokalaemia, similarly to the studies with liposomal amphotericin B, the continuous infusion of amphotericin B deoxycholate appears to reduce mainly pretubular renal toxicity 1,22 …”

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia

“…Furthermore, it appeared that the trial authors did not use premedication for prevention of infusion related toxicity, or supplementation with fluid, potassium and magnesium for prevention of nephrotoxicity although these precautions were known to be highly e ective when the trial was planned. Such preventive measures have been reported in other trials we have reviewed (Johansen 2000).…”